What is the role of consolidation therapy in the treatment of ovarian cancer?

Updated: Aug 10, 2020
  • Author: Andrew E Green, MD; Chief Editor: Yukio Sonoda, MD  more...
  • Print

Ovarian cancer has a very high response rate to front-line treatment; despite this, most patients develop recurrent cancer. Many groups have shown interest in research into treatments to prevent or prolong the interval of recurrence (such as consolidation therapy).

A Gynecologic Oncology Group protocol was discontinued when a statistical improvement in disease-free survival was demonstrated in patients receiving 12 months versus 3 months of additional monthly paclitaxel after initial therapy. [98] However, questions remain about this study, which was not completed as designed. Since no consensus on management in this situation exists, patients should be encouraged to participate in clinical trials of consolidation therapy.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!